Hydromethylthionine mesylate is under clinical development by TauRx Pharmaceuticals and currently in Phase III for Alzheimer’s Disease. According to GlobalData, Phase III drugs for Alzheimer’s Disease have a 12% phase transition success rate (PTSR) indication benchmark for progressing into Pre-Registration. GlobalData’s report assesses how Hydromethylthionine mesylate’s drug-specific PTSR and Likelihood of Approval (LoA) scores compare to the indication benchmarks. Buy the report here.
Smarter leaders trust GlobalData
GlobalData tracks drug-specific phase transition and likelihood of approval scores, in addition to indication benchmarks based off 18 years of historical drug development data. Attributes of the drug, company and its clinical trials play a fundamental role in drug-specific PTSR and likelihood of approval.
Hydromethylthionine mesylate overview
Hydromethylthionine mesylate (LMTX) is under development for the treatment of Alzheimer’s disease (AD), mild cognitive impairment, Parkinson’s disease and frontotemporal lobar degeneration syndromes (FTLD) including progressive supranuclear palsy and corticobasal degeneration syndrome. It is a small molecule administered orally. The drug candidate is a leuco-methylthioninium, a new chemical entity and a second-generation Tau aggregation inhibitor (TAI). It also acts on TDP-43 protein. It is based on proprietary drug discovery platform. It was also under development for the treatment of progressive non-fluent aphasia and behavioural-variant frontotemporal dementia (FTD-Pick’s Disease).
TauRx Pharmaceuticals overview
TauRx Pharmaceuticals (TauRx) discovers, develops and commercializes treatments and diagnostics for Alzheimer’s disease and other neurodegenerative diseases. The company’s pipeline products include LMTX, a tau aggregation inhibitor (TAI) for Alzheimer’s and Behavioural variant frontotemporal dementia diseases and early-stage compounds for use in therapies for neurodegenerative diseases. TauRx novel tau aggregation inhibitors target the formation of tau protein tangles in the brain. It operates a research facility located in Aberdeen, Scotland. It undertakes clinical trials for several drugs and works in partnership with academic institutions and other pharmaceutical companies active in the field of the neurodegeneration. TauRx is headquartered in Singapore City, Singapore.
For a complete picture of Hydromethylthionine mesylate’s drug-specific PTSR and LoA scores, buy the report here.
Data Insights
From
The gold standard of business intelligence.
Blending expert knowledge with cutting-edge technology, GlobalData’s unrivalled proprietary data will enable you to decode what’s happening in your market. You can make better informed decisions and gain a future-proof advantage over your competitors.
GlobalData, the leading provider of industry intelligence, provided the underlying data, research, and analysis used to produce this article.
GlobalData’s Likelihood of Approval analytics tool dynamically assesses and predicts how likely a drug will move to the next stage in clinical development (PTSR), as well as how likely the drug will be approved (LoA). This is based on a combination of machine learning and a proprietary algorithm to process data points from various databases found on GlobalData’s Pharmaceutical Intelligence Center.
